MTD — Mettler-Toledo International, I

Is MTD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

Mettler-Toledo International, I (MTD) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $1399.67. The rating moved from Neutral to Overbought on August 8, 2026.

See all overbought Healthcare stocks →

AI analysis

Mettler-Toledo is a high-quality, cash-generative instrument and services business with durable competitive advantages: a global installed base, recurring consumables and service revenue, and exposure to pharma/biotech tailwinds. Recent positive momentum in biologics and diagnostics supports near-term demand from CROs/CDMOs and lab customers. The company’s strong margins and balance sheet provide flexibility for R&D, selective M&A, and shareholder returns. Near-term performance will hinge on end-market capex trends, FX, and supply-chain stability. Base-case outlook is continued steady revenue growth and margin resilience, while downside scenarios include cyclical capex weakness or valuation multiple contraction.

Key factors

  • Leading market position in precision instruments and lab/industrial measurement with a large installed base that supports recurring service and consumable revenue
  • High margins and strong free cash flow generation enabling reinvestment in R&D, selective M&A, and shareholder returns (buybacks/dividends)
  • Diversified end-market exposure including pharmaceuticals, biotech, food, and industrial customers which cushions against single-market shocks
  • Readthrough from recent positive biologics/oncology clinical data (mRNA/biologics momentum) that can boost demand from CROs/CDMOs and biopharma customers
  • Pricing power and strong brand/reliability reputation, supporting margin resilience even during moderate volume cycles
  • Healthy balance sheet and conservative capital allocation that reduce downside risk in a slower macro environment

Risks

  • Premium valuation: the share price already reflects a high-quality business; near-term upside depends on continued execution and multiple expansion
  • Cyclical exposure to industrial and lab capital expenditure; an unexpected macro slowdown or muted pharma capex could pressure revenues
  • Foreign exchange volatility given significant international revenue exposure
  • Supply chain disruptions or component shortages could delay shipments and compress near-term margins
  • Regulatory or compliance issues for measurement devices in key industries (pharma/food) could lead to recalls, remediation costs, or lost sales
  • Execution risk from acquisitions or new product rollouts reducing near-term profitability if not integrated effectively

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MTD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.